Bellevue Life Sciences Acquisition Operating Income

As of the most recent data (June 2026), BLAC shows a operating income of $-17M. That compares with $-11M in the prior-year period — down 57.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLAC's operating income is now $-17M (was $-11M) — a 57.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition is outperforming or lagging.

Tracking BLAC's operating income over time shows whether Bellevue Life Sciences Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $-17M That compares with $-11M in the prior-year period — down 57.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Bellevue Life Sciences Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-17M) with ownership activity and broader fundamentals.